chlorthalidone has been researched along with Kidney Failure, Chronic in 17 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 9.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 5.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "Stroke: common 'GG' homozygotes had higher risk on lisinopril versus amlodipine [hazard ratio (HR)=1." | 5.14 | Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| " Hypertensive participants 55 years or older with at least 1 other coronary heart disease risk factor were randomized to receive chlorthalidone, amlodipine, or lisinopril for a mean of 4." | 5.11 | Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, M; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2005) |
| "Chlorthalidone was superior to (1) doxazosin mesylate in preventing combined CVD (CCVD) (risk ratio [RR], 1." | 2.74 | ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. ( Alderman, MH; Black, HR; Cushman, WC; Cutler, JA; Davis, BR; Einhorn, PT; Ford, CE; Haywood, LJ; Margolis, KL; Oparil, S; Pressel, SL; Probstfield, JL; Rahman, M; Whelton, PK; Wright, JT, 2009) |
| "The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (35.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayer, MK | 1 |
| Edwards, NC | 1 |
| Slinn, G | 1 |
| Moody, WE | 1 |
| Steeds, RP | 1 |
| Ferro, CJ | 1 |
| Price, AM | 1 |
| Andujar, C | 1 |
| Dutton, M | 1 |
| Webster, R | 1 |
| Webb, DJ | 1 |
| Semple, S | 1 |
| MacIntyre, I | 1 |
| Melville, V | 1 |
| Wilkinson, IB | 1 |
| Hiemstra, TF | 1 |
| Wheeler, DC | 1 |
| Herrey, A | 1 |
| Grant, M | 1 |
| Mehta, S | 1 |
| Ives, N | 1 |
| Townend, JN | 1 |
| Whittle, J | 1 |
| Lynch, AI | 2 |
| Tanner, RM | 1 |
| Simpson, LM | 1 |
| Davis, BR | 7 |
| Rahman, M | 6 |
| Whelton, PK | 6 |
| Oparil, S | 3 |
| Muntner, P | 1 |
| Moes, AD | 1 |
| Hesselink, DA | 1 |
| van den Meiracker, AH | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Boerwinkle, E | 1 |
| Ford, CE | 3 |
| Eckfeldt, JH | 3 |
| Leiendecker-Foster, C | 1 |
| Arnett, DK | 1 |
| Wright, JT | 5 |
| Probstfield, JL | 1 |
| Cushman, WC | 1 |
| Pressel, SL | 2 |
| Cutler, JA | 2 |
| Einhorn, PT | 2 |
| Haywood, LJ | 2 |
| Margolis, KL | 1 |
| Black, HR | 1 |
| Alderman, MH | 1 |
| Onuigbo, MA | 1 |
| Piller, LB | 1 |
| Barzilay, JI | 1 |
| Brown, CD | 1 |
| Colon, PJ | 1 |
| Fine, LJ | 1 |
| Grimm, RH | 1 |
| Gupta, AK | 1 |
| Baimbridge, C | 1 |
| Henriquez, MA | 1 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Pressel, S | 2 |
| Nwachuku, C | 2 |
| Barzilay, J | 2 |
| Batuman, V | 2 |
| Farber, M | 1 |
| Henriquez, M | 2 |
| Kopyt, N | 2 |
| Louis, GT | 2 |
| Saklayen, M | 2 |
| Stanford, C | 2 |
| Walworth, C | 2 |
| Ward, H | 2 |
| Wiegmann, T | 2 |
| Farber, MA | 1 |
| Franklin, S | 1 |
| Brunner, HR | 1 |
| Gavras, H | 1 |
| Waeber, B | 1 |
| Breslau, NA | 1 |
| Pak, CY | 1 |
| Canavese, JC | 1 |
| Fabre, J | 1 |
| Modai, D | 1 |
| Cohen, N | 1 |
| Weissgarten, J | 1 |
| Segal, B | 1 |
| Pik, A | 1 |
| Teodoresco, P | 1 |
| Câmpeanu, A | 1 |
| Schmidt, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395] | Phase 3 | 49 participants (Actual) | Interventional | 2013-01-18 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for chlorthalidone and Kidney Failure, Chronic
| Article | Year |
|---|---|
ALLHAT: still providing correct answers after 7 years.
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bla | 2010 |
Hypoparathyroidism.
Topics: Acetazolamide; Adenylyl Cyclases; Antacids; Bone and Bones; Calcium; Chlorthalidone; Dihydroxycholec | 1979 |
7 trials available for chlorthalidone and Kidney Failure, Chronic
| Article | Year |
|---|---|
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.
Topics: Adult; Aged; Chlorthalidone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fo | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2009 |
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; C | 2009 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
8 other studies available for chlorthalidone and Kidney Failure, Chronic
| Article | Year |
|---|---|
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Enhancement by diuretics of the antihypertensive action of long-term angiotensin converting enzyme blockade.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Child; | 1980 |
[The diuretics in the treatment of arteriol hypertension].
Topics: Amiloride; Benzothiadiazines; Chlorthalidone; Diuretics; Ethacrynic Acid; Furosemide; Humans; Hypert | 1976 |
Symptomatic renal artery stenosis superimposed on chronic glomerulonephritis.
Topics: Antihypertensive Agents; Cardiomegaly; Chlorthalidone; Chronic Disease; Creatinine; Furosemide; Glom | 1985 |
[Effects of clonidine treatment in advanced forms of essential arterial hypertension].
Topics: Aged; Aortic Arch Syndromes; Bradycardia; Cerebral Hemorrhage; Chemical Phenomena; Chemistry; Chlort | 1973 |
[Diuresis and diuretics].
Topics: Acetazolamide; Acute Disease; Agranulocytosis; Anuria; Biological Transport; Blood Platelet Disorder | 1971 |